China's first COVID-19 vaccine patent.
The adenovirus vector vaccine developed by Chen Wei of the Academy of Military Medical Sciences and Conceino Biological Products Co., Ltd., a biotechnology company in China, obtained the first patent of coronavirus pneumonia-19 vaccine in China.
According to China National Intellectual Property Administration.
According to China National Intellectual Property Administration News, the patent application for COVID-19 vaccine, an adenovirus vector jointly submitted by Chen Wei, a military medical research institute, and Kangxinuo Bio, a China biotechnology company, was recently approved, which is the first COVID-19 vaccine patent in China.
This patent was filed on March 65, 2008.
And was approved on August 1 1 2008.
According to the patent documents.
According to the patent documents, the patent was applied on March 8 this year and granted on August 8 1 1.
vaccine
Known as "Ad5-nCoV"
Using attenuated cold virus to introduce geic substance from novel coronavirus into human body. The goal is to train the body to produce antibodies that recognize coronavirus spike proteins and repel them.
The vaccine named "Ad5-nCoV" takes the attenuated common cold virus as the carrier, and transfers the genetic material of novel coronavirus into human cells, with the aim of training human bodies to produce antibodies that can recognize and fight COVID-19 spike protein.
The phase O clinical trial of the vaccine found that it was safe and could induce immune response.
According to research published in The Lancet magazine last month.
The results of the second clinical trial of the vaccine were published in The Lancet magazine last month. Experiments show that the vaccine is safe and can induce immune response.
the three phase of clinical trial
This will involve more participants and take place overseas.
Preparations are currently under way.
Phase III clinical trials will be conducted in more overseas subjects and are being promoted.